Xcout Intel
Hansa Biopharma
Hansa Biopharma is a Swedish biotechnology company focused on enzyme-based immunomodulation, including Idefirix (imlifidase), which is used to desensitize highly sensitized patients so they can receive kidney transplants. It serves transplant centers, healthcare professionals, and patients with serious immune-mediated conditions, and is also developing other therapies for autoimmune diseases and transplant medicine.
Subscribe to see Hansa Biopharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Hansa Biopharma at a glance
Hansa Biopharma is a biotech company headquartered in Sweden. Xcout tracks 15 named people at Hansa Biopharma, including Renee Aguiar-Lucander (Chief Executive Officer). Xcout recorded 16 job postings from Hansa Biopharma in the last 90 days.
Hansa Biopharma leadership
- Renee Aguiar-LucanderChief Executive Officer
- Maria TornsenChief Operating Officer and President U.S.
- Adam CutlerChief Financial Officer
- Brian GormanChief Legal Officer and Corporate Secretary
- Frank BringstrupChief Regulatory Affairs Officer
- Hitto KaufmannChief Scientific & Technology Officer
9 more named people on record for Hansa Biopharma, with roles, board committees and tenure — see the full roster →
Hiring at Hansa Biopharma
Xcout recorded 16 job postings from Hansa Biopharma in the last 90 days, from a hiring record Xcout has kept since September 2026.
The weekly hiring trend, the roles and locations behind it — see Hansa Biopharma's hiring signals →
Hansa Biopharma competitors
A few of Hansa Biopharma's closest competitors — see the full list of competitors and alternatives →
Hansa Biopharma AB (publ) is a biopharmaceutical firm specializing in the creation of immunomodulatory treatments. Leveraging its unique enzyme technology platform, the company aims to facilitate organ transplants and tackle rare autoimmune conditions driven by immunoglobulin G (IgG), alongside developing solutions for gene therapy and cancer. Its flagship therapeutic candidate, Imlifidase, is an enzyme-based therapy designed to break down antibodies. This compound is currently undergoing Phase 3 clinical trials for use in patients receiving sensitized kidney transplants and those suffering from anti-GBM antibody disease. Additionally, Imlifidase is in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. The company's development pipeline also includes NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing), intended for repeated administration in autoimmune disorders, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement), a cancer immunotherapy. Furthermore, Hansa Biopharma has established a preclinical research collaboration with argenx BV to evaluate the combined therapeutic potential of their respective IgG-modulating technologies. Established in 2007, the company's base of operations is located in Lund, Sweden.
Opsona Therapeutics was an Irish biotechnology company developing antibody-based therapeutics that modulate Toll-like receptor signaling in inflammatory and immune-mediated diseases. Its programs included OPN-305, an anti-TLR2 antibody investigated for conditions including delayed graft function after kidney transplantation, serving patients with serious inflammatory disorders and potential pharmaceutical partners.
Calliditas Therapeutics AB is a commercial-stage biopharma company based in Stockholm, Sweden. It focuses on developing and commercializing pharmaceutical products.
Genovis is a Swedish biotechnology company that develops and commercializes enzymes and enzyme-based technologies used in the development, characterization, and quality control of biopharmaceuticals. Its customers include pharmaceutical and biotechnology companies, as well as research and analytical laboratories.
Circio Holding ASA is a biotechnology company that develops novel circular RNA and immunotherapy medicines, utilizing its proprietary circVec platform to enhance gene therapy for genetic diseases. It serves the biopharmaceutical sector and patients with genetic disorders by advancing clinical programs and engaging in research collaborations.
Immunicum AB is a Swedish biotechnology company that developed allogeneic cell-based cancer immunotherapies, including the investigational product ilixadencel. Its programs were aimed at stimulating patients’ immune systems to treat solid tumors, serving oncology patients and healthcare providers.
Get Hansa Biopharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Hansa Biopharma? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Hansa Biopharma in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access